What is Relay Therapeutics, Inc.'s market cap?

Relay Therapeutics, Inc. (RLAY) has a market capitalization of $4.1B and trades on NASDAQ.

What is Relay Therapeutics, Inc.'s revenue and profitability?

Relay Therapeutics, Inc. generated $10.7M in trailing twelve-month revenue with a net loss of $272.7M, representing a net margin of -2554.1%. These figures are based on the Q1 2026 filing.

Who are Relay Therapeutics, Inc.'s competitors?

Relay Therapeutics, Inc.'s key competitors include Schrödinger, Revolution Medicines, Rallybio Corporation Common Stock, and others. These companies compete in similar markets and product categories.

Who does Relay Therapeutics, Inc. partner with?

Relay Therapeutics, Inc.'s notable partners include Roche, Genentech.

Where is Relay Therapeutics, Inc. headquartered?

Relay Therapeutics, Inc. is headquartered in United States of America and employs approximately 309 people. It has been publicly traded since 2020.

Relay Therapeutics, Inc.

RLAY

Relay Therapeutics is a clinical-stage precision medicine company focused on developing small molecule therapies for oncology and genetic diseases.

Market cap

$4.06B+553%

Revenue$10.7M+39.0%

Net income-$272.7M+18.2%

EPS (diluted)-$1.56+29.1%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$3.0MMiss by $2.6M EPS-$0.41Miss by $0.06

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$960.0K

EPS estimate-$0.41

Financials

Q1 2026

Income statement

See full

Revenue$3.0M-60.9%

Operating income-$78.6M+7.4%

Net income-$73.3M+4.9%

EPS (diluted)-$0.41+10.9%

Balance sheet

See full

Cash & equivalents$204.6M+119%

Total debt$31.6M-33.1%

Total equity$642.2M-10.9%

Total assets$699.6M-12.5%

Cash flow

See full

Operating cash flow-$51.1M+30.2%

Valuation & ratios

Valuation

See full

Market cap$4.06B+553%

Enterprise value$3.89B+601%

P/S380.5×+305×

Profitability

See full

Operating margin-2,776.6%-820pp

Net margin-2,554.1%-745pp

Returns & leverage

See full

Return on equity-40%-4.3pp

Debt / equity0×0.0×

Current ratio22.1×+2.2×

Competitors

By market cap

Revolution Medicines, Inc.$40.0B+476%

Ligand Pharmaceuticals$6.0B+129%

Relay Therapeutics, Inc.$4.1B+540%

Schrodinger$1.1B-30.5%

Zevra Therapeutics, Inc.$574.0M-2.9%

Fulcrum Therapeutics, Inc.$248.5M-41.0%

Polaryx Therapeutics, Inc. $97.7M—

Rallybio Corporation$86.6M+313%

By revenue growth

Zevra Therapeutics, Inc.+201%

Ligand Pharmaceuticals+51.2%

Relay Therapeutics, Inc.+39.0%

Schrodinger+10.6%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

Ligand Pharmaceuticals55.95%+129pp

Schrodinger-68.49%+4.4pp

Relay Therapeutics, Inc.-2,554.14%+1,787pp

Revolution Medicines, Inc.-76,423.32%—

Profile

Relay Therapeutics is a clinical-stage precision medicine company focused on developing small molecule therapies for oncology and genetic diseases. The company utilizes its proprietary Dynamo platform to integrate computational and experimental techniques, enabling Motion-Based Drug Design by analyzing protein dynamics rather than static structures.

Competitive position

A pioneer in motion-based drug design utilizing a proprietary computational platform to target previously undruggable protein conformations.

GeographiesUnited States

Customer segmentsPatients, Clinical trial participants

Business modelR&D intensive, Drug development

SuppliersComputational hardware providers, Laboratory equipment suppliers, Contract research organizations, Genomic data providers

CustomersHospitals, Specialty pharmacies, Oncology clinics

CountryUnited States of America

Listed2020

Employees309.0

CEOSanjiv K. Patel

SectorHealthcare

IndustryBiotechnology

Websiterelaytx.com

FilingsSEC EDGAR

Ask your AI about Relay Therapeutics, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s market cap?: Relay Therapeutics, Inc. (RLAY) has a market capitalization of $4.1B and trades on NASDAQ.
What is Relay Therapeutics, Inc.'s revenue and profitability?: Relay Therapeutics, Inc. generated $10.7M in trailing twelve-month revenue with a net loss of $272.7M, representing a net margin of -2554.1%. These figures are based on the Q1 2026 filing.
Who are Relay Therapeutics, Inc.'s competitors?: Relay Therapeutics, Inc.'s key competitors include Schrödinger, Revolution Medicines, Rallybio Corporation Common Stock, and others. These companies compete in similar markets and product categories.
Who does Relay Therapeutics, Inc. partner with?: Relay Therapeutics, Inc.'s notable partners include Roche, Genentech.
Where is Relay Therapeutics, Inc. headquartered?: Relay Therapeutics, Inc. is headquartered in United States of America and employs approximately 309 people. It has been publicly traded since 2020.